Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Comment by mtvrdonon Mar 06, 2017 4:44pm
143 Views
Post# 25939933

RE:can anyone explain to me why health canada approved improved

RE:can anyone explain to me why health canada approved improved

It's more than an approval, there is a significant new component to the technology that can now be sold and marketed.   It's also a number of things coming together.

On average their trading range was about 17 or 18 cents for most of the last year.    So, they are presently trading about 2.5 times where they were, not 9 times.   Of course, 9 times would be nice... 

Under prior approvals, it was primarily for specialized use on young children because it examined measured the morphology of the right ventricle of a heart.   That limited the application to specialized pediatic applications and there are relatively few specialized facilities/practitioners to sell to.  

With the new version of the technology and the new Health Canada approval, the technology examines the entire heart and can be used for many more clinical applications.   Where it was a piece of tech that was very specialized before, now it becomes a valuable piece of equipment in any cardiac care facility.   So, the market in Canada got much bigger (thousands of facilities versus a few specialized pediatric cardiology applications).   It can also piggy-back on existing ultrasound systems which many facilities already have.   Bottom line .... much bigger market and lots of potential for a takeout by existing Ultrasound companies. 

They also got some more funding and exposure.   Funding was an issue before, because they had just been through the very challenging and expensive process of getting FDA approval.
 

Bullboard Posts